Abstract
We report the case of a 44-year-old male patient with an aggressive silent corticotroph cell pituitary adenoma, subtype 2. In that it progressed to carcinoma despite temozolomide administration, anti-VEGF therapy was begun. MRI, PET scan and pathologic analysis were undertaken. After 10 months of anti-VEGF (bevacizumab) treatment no progression of the lesion was noted. The tumor was biopsied and morphological analysis showed severe cell injury, vascular abnormalities and fibrosis. Bevacizumab treatment has continued for additional 16 months to present with stabilization of disease as documented on serial MRI and PET scans. This is the first case of a bevacizumab-treated pituitary carcinoma with long-term, now 26 months, control of disease. The present findings are promising in that anti-angiogenic therapy appears to represent a new option in the treatment of aggressive pituitary tumors.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
The term angiogenesis denotes the neoformation of blood vessels [1]. Oxygen plays an important role in its regulation through Hypoxia-Inducible Factor (HIF) [2]. Recognition that control of the process has therapeutic implications inspired extensive research [3]. Stimulation of angiogenesis is of therapeutic importance in ischemic heart disease, peripheral vascular disease, and wound healing [4]. Inhibition of angiogenesis may be of therapeutic value in various types of cancer in and age-related macular degeneration [5–7]. Increased vascularity leading to accelerated tumor growth was reported in several tumor types. Folkman suggested that anti-angiogenesis could be an effective strategy in the treatment of tumors [8].
Subject and methods
Case report
A 38-year-old male patient with an aggressive silent corticotroph cell adenoma, subtype 2 presented in 2005. After four prior surgeries and radiotherapy, tumor persisted and grew (Fig. 1a). A subtotal resection was undertaken (Fig. 1b). Temozolomide (TMZ) was administered at a standard-dose and regimen (200 mg/m2/day, 5/28) for 8 months (Fig. 1c) but without response. He was again operated (Fig. 1d). TMZ was restarted at the same dose and continued for 16 months, during which time he developed two vertebral metastases at levels C2 and T1. Both were confirmed by surgery and pathology (Fig. 1e). Since 06-methylguanine-DNA methyltransferase (MGMT) immunoexpression was high, TMZ was administered in a metronomic dose (75 mg/m2/day continuously, 28/28) in order to deplete MGMT. Focal radiotherapy to the spine was also undertaken. Eight months later, a sellar tumor regrowth was noted (Fig. 1f), which prompted reoperation (Fig. 1g). Histologically, as documented in a prior publication, the tumor showed no morphological change [9]. Conclusive VEGF immunoreactivity was found in the cytoplasm of tumor cells. Intravenous bevacizumab therapy was started at 10 mg/kg every 2 weeks. At 10 months, no progression was noted and the tumor was biopsied. Bevacizumab treatment has continued for additional 16 months. Presently, after 26 months of treatment, resultant stabilization of the disease is documented on serial MRI and PET scans (Fig. 1h, i). No new metastases were noted.
Pathology
The surgically removed tumor was formalin-fixed, paraffin-embedded, sectioned at 5 microns and stained with hematoxylin-eosin and the periodic acid-Schiff (PAS) method. Immunohistochemistry employed the streptavidin biotin peroxidase complex method. For transmission electron microscopy, glutaraldehyde-fixed, osmicated, Epon-embedded tissue was studied on a Hitachi 7650 transmission electron microscope.
Results
Pathology
The specimen resected at the 10th month of bevacizumab therapy showed severe cellular injury and fibrosis. When compared with the previous specimens (Fig. 2a), both the ACTH and β-endorphin immunopositive tumor cells were ultrastructurally smaller, many but not all having undergone cytoplasmic vacuolization and rupture of cell membranes (Fig. 2b). Fibrosis was extensive, mainly affecting vessels in perivascular zones (Fig. 2c). Large, irregular vessels with thick walls as were many thin walled, newly formed vessels were highlighted on endoglin immunostaining. Whether the vascular changes and the cellular damage more dramatically noted ultrastructurally are related to bevacizumab therapy is unclear. The patient had twice undergone radiotherapy before the latest surgery. This may have contributed to the severe fibrosis observed, but the specimen obtained 1 year after radiotherapy revealed none. Thus, our sequential morphologic analyses suggest that the cell injury, vascular abnormalities, and fibrosis are the effects of bevacizumab therapy.
Discussion
The vascular endothelial growth factor (VEGF) family consists of five glycoproteins, VEGFA through D as well as placental growth factor (PGF). Of these, VEGFA is best characterized and commonly referred as VEGF [1]. It binds to three transmembrane tyrosine kinase receptors and is predominantly found on endothelial cells. VEGF affects endothelial cell proliferation and survival, chemotaxis of bone marrow-derived progenitor cells, vasodilatation and vascular permeability. VEGF and its receptors are key regulators of angiogenesis, and are regarded as prime therapeutic targets.
Targeting VEGF is intended to prevent the formation of new vasculature, blocking new vessel growth thus inhibiting tumor growth. Anti-angiogenic therapy can sensitize tumor stem cells to radio- and chemotherapy approaches to inhibit VEGF signaling include antibody neutralization of the ligand or receptor and blocking VEGF activation and signaling using tyrosine kinase inhibitors [10]. Bevacizumab, a recombinant, humanized, anti-VEGF monoclonal antibody, prevents the binding of VEGF to endothelial surface receptors [11, 12]. As an angiogenesis inhibitor delays tumor growth and it is used in the treatment of colorectal non-small cell pulmonary, renal and breast carcinoma, as well as recurrent anaplastic astrocytoma and glioblastoma [13–17]. Recently, it has been proved useful in the treatment of cerebral radiation necrosis [18]. Having a circulating half-life of ~20 days, its optimal dose is 5–10 mg/kg every 2 weeks.
Pituitary carcinomas present a major therapeutic challenge. The spectrum of adjuvant therapies has proven palliative at best. Since 2006, temozolomide (TMZ) has been found efficacious in aggressive pituitary adenomas and carcinomas, the response rate being approximately 60% [19, 20].
This is the first case of a bevacizumab-treated pituitary carcinoma with long-term control of disease, now 26 months. Understandably, the present findings prompt enthusiasm in that anti VEGF therapy appears to represent a new option in the treatment of pituitary carcinoma. Nonetheless, more cases must be investigated before recommending the treatment. Caution is in order given the significant side effects of bevacizumab, including hypertension, hemorrhage, thrombosis, embolism, cerebrovascular ischemia, gastrointestinal perforation and impaired wound healing [21, 22].
Another important problem stems from the well known occurrence of tumor cell heterogeneity. Since several mutations may occur during neoplastic progression, tumor cells may respond differently. For example, some cells do not need much oxygen to thrive. Although some may die under hypoxic conditions, others survive, especially perivascular tumoral cells, successfully multiplying, invading and even giving rise to metastases [23–26]. Thus, it may be advisable to combine bevacizumab with chemotherapeutic agents, perhaps irinotecan or temozolomide [27], because bevacizumab does not seem to have direct cytolytic effect but besides its anti-angiogenic action it could sensitize tumoral cells to chemotherapy.
References
Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8(8):579–591. doi:10.1038/nrc2403
Zagzag D, Lukyanov Y, Lan L, Ali MA, Esencay M, Mendez O, Yee H, Voura EB, Newcomb EW (2006) Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 86(12):1221–1232. doi:10.1038/labinvest.3700482
Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362(6423):841–844. doi:10.1038/362841a0
Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358(19):2039–2049. doi:10.1056/NEJMra0706596
Wilson WR, Hay MP (2011) Targeting hypoxia in cancer therapy. Nat Rev Cancer 11(6):393–410. doi:10.1038/nrc3064
Gaur P, Bose D, Samuel S, Ellis LM (2009) Targeting tumor angiogenesis. Semin Oncol 36(2 suppl 1):S12–S19. doi:10.1053/j.seminoncol.2009.02.002
Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364(20):1897–1908. doi:10.1056/NEJMoa1102673
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182–1186. doi:10.1056/NEJM197111182852108
Moshkin O, Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Uribe H, Gonzalez R, Cusimano M, Horvath E, Rotondo F, Kovacs K (2011) Aggressive silent corticotroph adenoma progressing to pituitary carcinoma. The role of temozolomide therapy. Hormones (Athens) 10(2):162–167
Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353(2):172–187. doi:10.1056/NEJMra044389
Ferrara N, Hillan KJ, Novotny W (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333(2):328–335. doi:10.1016/j.bbrc.2005.05.132
Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57(20):4593–4599
Chamberlain MC, Johnston S (2009) Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neurooncol 91(3):359–367. doi:10.1007/s11060-008-9722-2
Jouanneau E (2008) Angiogenesis and gliomas: current issues and development of surrogate markers. Neurosurgery 62(1):31–50. doi:10.1227/01.NEU.0000311060.65002.4E00006123-200801000-00003 discussion 50–32
Norden AD, Drappatz J, Wen PY (2008) Antiangiogenic therapy in malignant gliomas. Curr Opin Oncol 20(6):652–661. doi:10.1097/CCO.0b013e32831186ba00001622-200811000-00009
Norden AD, Drappatz J, Muzikansky A, David K, Gerard M, McNamara MB, Phan P, Ross A, Kesari S, Wen PY (2009) An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol 92(2):149–155. doi:10.1007/s11060-008-9745-8
Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM (2010) Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 120(3):694–705. doi:10.1172/JCI4028340283
Torcuator R, Zuniga R, Mohan YS, Rock J, Doyle T, Anderson J, Gutierrez J, Ryu S, Jain R, Rosenblum M, Mikkelsen T (2009) Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol 94(1):63–68. doi:10.1007/s11060-009-9801-z
Syro LV, Ortiz LD, Scheithauer BW, Lloyd R, Lau Q, Gonzalez R, Uribe H, Cusimano M, Kovacs K, Horvath E (2011) Treatment of pituitary neoplasms with temozolomide: a review. Cancer 117(3):454–462. doi:10.1002/cncr.25413
McCormack AI, Wass JA, Grossman AB (2011) Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Invest. doi:10.1111/j.1365-2362.2011.02520.x
Tebbutt NC, Murphy F, Zannino D, Wilson K, Cummins MM, Abdi E, Strickland AH, Lowenthal RM, Marx G, Karapetis C, Shannon J, Goldstein D, Nayagam SS, Blum R, Chantrill L, Simes RJ, Price TJ (2011) Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Ann Oncol 22(8):1834–1838. doi:10.1093/annonc/mdq702
Norden AD, Drappatz J, Ciampa AS, Doherty L, LaFrankie DC, Kesari S, Wen PY (2009) Colon perforation during antiangiogenic therapy for malignant glioma. Neuro Oncol 11(1):92–95. doi:10.1215/15228517-2008-071
Helfrich I, Scheffrahn I, Bartling S, Weis J, von Felbert V, Middleton M, Kato M, Ergun S, Schadendorf D (2010) Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med 207(3):491–503. doi:10.1084/jem.20091846
Azam F, Mehta S, Harris AL (2010) Mechanisms of resistance to antiangiogenesis therapy. Eur J Cancer 46(8):1323–1332. doi:10.1016/j.ejca.2010.02.020
Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15(3):220–231. doi:10.1016/j.ccr.2009.01.027
Cheshier SH, Kalani MY, Lim M, Ailles L, Huhn SL, Weissman IL (2009) A neurosurgeon’s guide to stem cells, cancer stem cells, and brain tumor stem cells. Neurosurgery 65(2):237–249. doi:10.1227/01.NEU.0000349921.14519.2A00006123-200908000-00003; discussion 249–250; quiz N236
Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733–4740. doi:10.1200/JCO.2008.19.8721
Acknowledgments
Authors are grateful to the Jarislowsky and Lloyd Carr Harris Foundations for their continuous support. The authors thank Mrs. Denise Chase of Mayo Clinic for excellent assistance and secretarial support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ortiz, L.D., Syro, L.V., Scheithauer, B.W. et al. Anti-VEGF therapy in pituitary carcinoma. Pituitary 15, 445–449 (2012). https://doi.org/10.1007/s11102-011-0346-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11102-011-0346-8